Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | TYK2 | P29597 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28936188 | 1.00 | MEN1 (0.50) | MEN1MAPK10GFERKMT2ACCNE1 | |
| SCHEMBL10172152 | 0.79 | NPC1 (0.47) | MEN1KMT2ANPC1JAK2TYK2 | |
| SCHEMBL29391624 | 0.78 | KMT2A (0.76) | MEN1MAPK10GFERKMT2ANPC1 | |
| SCHEMBL221242 | 0.78 | KMT2A (0.76) | MEN1MAPK10GFERKMT2ANPC1 | |
| SCHEMBL857502 | 0.78 | NPC1 (0.63) | MEN1KMT2ACDK2NPC1EGFR | |
| SCHEMBL16926547 | 0.78 | MEN1 (0.53) | MEN1MAPK10GFERKMT2ANPC1 | |
| SCHEMBL4595845 | 0.77 | KMT2A (0.48) | MEN1MAPK10GFERKMT2ACDK2 | |
| SCHEMBL29919765 | 0.77 | NPC1 (0.46) | MEN1KMT2ANPC1JAK2TYK2 | |
| SCHEMBL28936138 | 0.77 | NPC1 (0.46) | MEN1KMT2ANPC1JAK2TYK2 | |
| SCHEMBL31247411 | 0.77 | NPC1 (0.50) | MEN1KMT2ALCKNPC1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NANJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289719-A1 | HETEROCYCLIC COMPOUNDS AS MNK INHIBITORS | NIM1K, MAP3K1, MAPKAPK2 | MEN1 491/4885MAPK10 55/4885GFER 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.